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Objective: In this study, we aimed to examine somatisation as a risk factor for the onset of depressive and anxiety
disorders.
Methods: 4-year follow-up data from the Netherlands Study of Depression and Anxiety (NESDA), a multisite co-
hort study of the course of depression and anxiety, was analysed. Participants (18–65 years) without a lifetime
depressive or anxiety disorder at baseline were included (n = 611). Somatisation was measured at baseline
with the somatisation subscale of the 4 Dimensional Symptoms Questionnaire. Onset of depression and anxiety
was assessed with the CIDI interview at 2-year and 4-year follow-up.
Results: Somatisation was a risk factor for the incidence of depression [Hazard Ratio per unit increase (HR); 95%
Conﬁdence Interval (CI): 1.13; 1.09–1.17] and anxiety [HR; 95% CI: 1.14; 1.09–1.18]. Associations attenuated but
remained statistically signiﬁcant after adjusting for socio-demographic characteristics, chronic somatic disorders,
and baseline levels of (subclinical) depressive or anxiety symptoms [adjusted HR for depression; 95% CI: 1.06;
1.00–1.12, adjusted HR for anxiety; 95% CI: 1.13; 1.07–1.20].
Conclusion: Personswho somatise have an increased risk of becoming depressed or anxious in subsequent years,
over and above baseline levels of depressive or anxiety symptoms. Theymay represent a target group for preven-
tion of depressive and anxiety disorders.© 2015 Elsevier Inc. All rights reserved.Introduction
Somatisation, a common phenomenon in primary care, is deﬁned as
“the tendency to experience and communicate somatic distress and
symptoms unaccounted for by pathological ﬁndings, to attribute them
to physical illness, and to seek medical help for them” [1], p. 1359.
While experiencing some physical symptoms unaccounted for by path-
ological ﬁndings is a common phenomenon, experiencing multiple un-
explained physical symptoms from different organ systems implies
somatisation [2]. Physical symptoms, such as fatigue, dizziness and
pain, are prevalent, often co-occurring and can range in severity with
syndromes such as somatic symptom disorder and functional somatic
syndromes (e.g. ﬁbromyalgia) at the severe end of the clinical spectrum
to self-limiting symptoms. These are especially prevalent in peoplewho
have mental health problems, such as depressive and anxiety disordersUniversity Medical Center,
an der Boechorststraat 7, D-549,
rsten).[3–5]. A cross-sectional study by Bekhuis et al. (2014) [5], for instance,
showed that depressive and anxiety disorders were moderately to
strongly associated with all clusters of somatic symptoms. Simon et al.
(1999) [4] found that half of the depressed patients in primary care
were somatising. Somatisation could also constitute an important risk
factor for the occurrence of these disorders and, therefore, persons
who somatisemay represent a target group for prevention of depressive
and anxiety disorders, which continues to be an important public health
goal [6–8]. However, as to date most studies that have investigated this
association have been cross-sectional, [3,9,10], thus precluding conclu-
sions about temporality, little is known about the actual risk of develop-
ing a depressive or anxiety disorder. Examining the relationship
between somatisation and the onset of depressive or anxiety disorders
is important as the co-occurrence of somatisation with mental health
problems affects health outcomes, functioning, and economic costs,
thus increasing the burden of disease. The presence of somatisation is
associatedwith less improvement of depressive and anxiety symptoms,
and is predictive of a poorer treatment response in depressed patients
[11]. In addition, the co-occurrence of symptoms of somatisation and
depression is associated with decreased physical, social, and occupa-
tional functioning and an increase of health care services use [8].
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tigated somatisation as a predictor for the onset of depressive or anxiety
disorders. Data from a primary care study showed that speciﬁc unex-
plained symptoms (e.g. fatigue, pain or dizziness) presented to the GP
were not predictive of subsequent depressive or anxiety disorder after
three months as recognised and registered by GPs, although the pres-
ence of unexplained symptoms increased the concurrent risk of depres-
sion or anxiety at least three-fold [12]. However, in a community study
somatisation predicted subsequent depressive symptoms at 5-year
follow-up in non-depressed women, but was not predictive in men,
after correction for depressive symptoms at baseline [13]. There is also
some evidence from community and primary care studies focusing on
speciﬁc medically unexplained physical symptoms (e.g. fatigue) that
these symptoms can increase the risk of subsequent psychiatric symp-
tomsanddisorders, including depression and anxiety [14–16]. Although
some of these studies focused onmedically unexplained physical symp-
toms, it is not clear whether these persons with medically unexplained
symptoms somatise.
Besides focusing on a speciﬁc symptom,most previous studies either
did not take psychiatric history into account, thus could not discrimi-
nate between incidence and recurrence, or did not use a clinical inter-
view but rather used self-report questionnaires to determine the
presence of a disorder at baseline and follow-up. Therefore, our study
aimed to examine whether somatisation is a risk factor for the subse-
quent onset of an incident depressive or anxiety disorder as determined
by a clinical interview in a longitudinal prospective cohort study.
Methods
Design
This study used 4-year prospective data from the Netherlands Study
of Depression andAnxiety (NESDA). The overall aim of the NESDA study
is to examine the aetiology, course and consequences of depression and
anxiety, using biological and psychosocial research paradigmswithin an
epidemiological framework. At baseline (2004–2007), 2981 partici-
pants aged 18 through 65 years were included in the study. The sample
consisted of healthy controls; personswith a prior history of depression
and/or anxiety; personswith a current depressive and/or anxiety disor-
der and persons at risk because of a family history or subthreshold de-
pressive or anxiety symptoms. Participants were recruited in different
settings: the community (n=564), primary care (n=1610), andmen-
tal health services (n= 807). Exclusion criteria were the presence of a
primary psychiatric diagnosis other than depression or anxiety, which
might interfere with the course trajectory (i.e. psychotic disorder, ob-
sessive compulsive disorder, bipolar disorder or severe addiction disor-
der), and lack of ﬂuency in the Dutch language. Baseline and follow-up
assessments consisted of a clinical interview, questionnaires, and phys-
ical measurements. The baseline, 2-year, and 4-year follow-up mea-
surements were used in this study. Further details on the selection
procedure and design of the NESDA study are provided elsewhere
[17]. The research protocol was approved by the ethical review boards
of the VU University Medical Center and all other participating insti-
tutes. All respondents provided written informed consent.
Study population
Participants who never had an episode of a depressive disorder
(major depressive disorder or dysthymia) or anxiety disorder (social
phobia, panic with agoraphobia, panic without agoraphobia, agorapho-
bia, generalised anxiety disorder) were included in this study (n =
652). Of these participants, 614 (94%) participated in at least
one follow-up measurement. Information on the central determinant
(i.e. somatisation)was available for 611 of these remaining participants.
For these participants, no information on the other variables was miss-
ing. These 611 participants represent our study sample.Measures
Onset of depressive and anxiety disorders
The Composite International Diagnostic Interview (CIDI, lifetime
version 2.1) [18] was administered at the 2-year and 4-year follow-up
assessments to determine the incidence (yes/no) of a depressive or anx-
iety disorder during the 4-year follow-up period. The CIDI is a highly re-
liable and valid assessment tool for depressive and anxiety disorders as
deﬁned by the DSM-IV criteria [18]. Incident depression or anxiety was
deﬁned as the occurrence of a depressive or anxiety disorder at any
point during the follow-up period.
Whendiagnosedwith a depressive or anxiety disorder at either the 2-
year or 4-year follow-upmeasurements, participants were asked to indi-
cate the time of onset of their disorder: less than two weeks ago, two
weeks to one month ago, one to six months ago, six to twelve months
ago, in the last twelve months, or more than one year ago. Time-at-risk
was calculated from baseline until the moment a participant had an
event (i.e. onset of a depressive or anxiety disorder), by taking the mid-
point of each time interval for onset. For instance, no depressive disorder
was diagnosed at 2-year follow-up, while at the 4-year follow-up mea-
surement, a participant reported the time of onset of a depressive disor-
der between six and twelvemonths ago. For this participant, time-at-risk
was set to 48 months− 9 months = 39 months. Time-at-risk was cen-
sored at 48months when the participant had not developed a depressive
or anxiety disorder during the follow-up period. For participants who did
not take part in the 4-year follow-upmeasurement, time-at-risk was cal-
culated over the 2-year follow-up. Participants who did not take part in
the 2-year follow-up measurement, but did take part in the 4-year
follow-up measurement, were asked about onset and recency of depres-
sive and anxiety disorders over a 4-year period at the 4-year follow-up
measurement and time to onset was calculated accordingly.
Somatisation
The somatisation subscale of the Four Dimensional Symptoms Ques-
tionnaire (4DSQ) [2] was used tomeasure somatisation in NESDA.While
experiencing one or few physical symptoms is considered normal,
experiencing multiple unexplained physical symptoms from different
organ systems indicates somatisation [1,2]. The 4DSQ somatisation sub-
scale operationalises somatisation as a high number and frequency of
physical symptoms and has been validated against various measures
(e.g. somatisation subscale of the SCL-90; GP's diagnoses) and in varying
samples, including psychiatric and primary care samples [2]. This sub-
scale consists of 16 symptoms (e.g. during the past week did you suffer
from dizziness; painful muscles; headache), which are scored on a
5-point Likert scale (‘no’, ‘sometimes’, ‘regularly’, ‘often’, and ‘very often
or constantly’). Responses were recoded (‘no’ = 0; ‘sometimes’ = 1;
‘regularly’ to ‘very often or constantly’ = 2) and item scores were sum-
mated to calculate scale scores (range 0–32) [2]. Missing items were re-
placed by the mean of the available items, under the condition that no
more than 6 out of 16 items were missing. No overall score could be cal-
culated for 3 out of 614 participants (0.5%). These participants were ex-
cluded from the analyses. An overall score of 11 or higher is considered
to be an indication of an elevated level of somatisation as well as an ele-
vated risk of impaired functioning. A score of 21 or higher indicates a
highly elevated score and a very high risk of impaired functioning [2].
Demographic variables
Age, gender, number of years of education, and work status were
assessed by self-report questionnaires.
Chronic somatic disorders
We also adjusted for the potential confounding effects of chronic so-
matic disorders (yes/no) in our analyses as thesemay be related to both
the reporting of somatic symptoms and the occurrence of depression or
anxiety [19]. Participants were asked to indicate whether they suffered
from any of the chronic somatic disorders listed in the interview and
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order. This interview instrument was designed for the Netherlands
Study of Depression and Anxiety. Only disorders for which treatment
or medication was needed were included. The disorders included:
lung disease, heart conditions, diabetes, stroke, arthritis, cancer, ulcers,
intestinal disorders, liver disease, epilepsy, thyroid disease, and other
chronic diseases. So-called functional somatic disorders (i.e. chronic fa-
tigue syndrome, irritable bowel syndrome and ﬁbromyalgia) were not
included as these primarily consist ofmedically unexplained symptoms,
which are the focus of our study.
Depressive and anxiety symptoms
As noted in the Introduction section, symptoms of depression and
anxiety are conceptually related to somatisation, and many depression
and anxiety measures in their turn tend to cover somatic items. In addi-
tion, high but subclinical levels of symptoms of depression and anxiety
are among the most important risk factors for the onset of depressive
and anxiety disorders [20]. Therefore we adjusted for baseline symp-
toms of depression and anxiety in our analyses. Depressive symptoms
were measured using the validated Quick Inventory of Depressive
Symptomatology (QIDS) [21]. The QIDS consists of sixteen items cover-
ing mood, cognitive and only few somatic features of a depressive epi-
sode. In our study sample, the QIDS correlated less with the 4DSQ
somatisation scale than the full IDS (r=0.58 versus r=0.67), the latter
including more items on somatic features. The items are scored on a
scale of 0 to 3, where zero indicates the absence of the symptom in
question. Items are summed to obtain a total score ranging from 0–27.
Missing items were replaced by the mean of the available items, under
the condition that no more than 3 out of 16 QIDS items were missing.
A higher score is indicative of more depressive symptoms. Anxiety
symptoms were measured with the subjective scale of the validated
Beck Anxiety Inventory (BAI), which consists of seven items covering
subjective and cognitive features of anxiety [22,23]. Items are scored
(0 to 3) on a 4-point Likert scale and added to obtain a total score, rang-
ing from 0–21 [22]. Again, a higher score is indicative of more anxiety
symptoms. The subjective scale of the BAI was used because of its
lower correlation (r = 0.48, p b .001) with the 4DSQ somatisation
scale compared to the complete BAI (r= 0.69, p b .001), which also in-
cludes items on somatic features of anxiety. Accordingly, the somatic
subscale of the BAI covers only these somatic features of anxiety.
Statistical analyses
Descriptive statistics were used to describe the sample characteris-
tics. Besides, Pearson correlations between baseline symptoms of
somatisation, depression and anxiety were calculated.
The associations between somatisation and the occurrence of a sub-
sequent depressive or anxiety disorderwere quantiﬁedwithHazard Ra-
tios (HRs). Cox regression analyses were used because they account for
differences in time-at-risk (i.e. person time), as inevitably there was
some loss-to follow-up. In all of the analyses, the somatisation score
was entered into the regression model as the central determinant of
the incidence of a depressive or anxiety disorder during the follow-up
period. The possible confounding effects of sociodemographic (age, gen-
der, education level, andwork status), somatic (presence of chronic dis-
ease), and psychiatric characteristics (subclinical depressive or anxiety
symptoms)were investigated by including these variables in the regres-
sion model in a stepwise manner. Analyses were performed with SPSS
(version 20) statistical software.
Results
Participants' characteristics
The baseline sample characteristics are presented in Table 1. Twelve
percent of the sample of 611persons scored at or above the cut-off scoreof 11 on the 4DSQ somatisation scale, indicating an elevated level of
somatisation and being at risk for impaired functioning. Only 5 partici-
pants (0.8%) scored in the highest range (21–32). Mean somatisation
scores at baseline were low [M (SD) = 5.0 (4.6)]. Somatisation was
moderately correlated with anxiety symptoms (r = 0.48, p b .001)
and depressive symptoms (r= 0.58, p b .001) at baseline.
Attrition analyses showed no signiﬁcant differences between partic-
ipants (n=611) and non-participants (n=41) for age [M (SD) = 41.0
(14.6) vs. 43.1 (16.2); t (650) = .91, p = .36], gender [female: 61% vs.
68%; χ2 (1) = .89, p = .35] and anxiety symptoms at baseline
[M (SD) = 1.35 (1.97) vs. 2.18 (3.20); t(38.8) = 1.58, p = .12.] There
was a slight, but statistically signiﬁcant difference in number of years
of education [M (SD) = 12.9 (3.21) vs. 11.2 (2.43); t(49.9) =−4.20,
p b .001], and depressive symptoms at baseline [M (SD) = 3.42 (3.09)
vs. 4.53 (3.42); t(647) = 1.90, p= 0.03].
During the 4-year follow-up, 95 participants (16%) became de-
pressed and/or anxious: 47 participants (8%) developed a depressive
disorder, 24 participants (4%) developed an anxiety disorder and 24
participants (4%) developed both a depressive and an anxiety disorder.
Somatisation as a predictor for an incident depressive or anxiety
disorder
The Hazard Ratios (HRs) of the association between somatisation
and the occurrence of an incident depressive disorder (with or without
anxiety), incident anxiety disorder (with or without depression), and
depressive and/or anxiety disorder during follow-up are displayed in
Table 2. This table shows that somatisation signiﬁcantly increased the
risk of a subsequent incident depressive disorder as one point increase
in the somatisation score increased the incidence rate of a depressive
disorder by 13% (HR = 1.13; 95% CI = 1.09 to 1.17; p b .001). After
adjusting for baseline levels of depressive symptoms as measured by
the QIDS, the association of somatisation with the onset of depressive
disorders was reduced but remained statistically signiﬁcant (HR =
1.06; 95% CI = 1.01 to 1.12; p = .032). Higher levels of somatisation
at baseline also signiﬁcantly increased the incidence rate of an anxiety
disorder (HR = 1.14; 95% CI = 1.09 to 1.18; p b .001, adjusted HR =
1.13; 95% CI = 1.07 to 1.20; p b .001). Similar results were found for
the onset of depressive and/or anxiety disorders: having a higher
somatisation score at baseline increased the risk of becoming depressed
or anxious (HR= 1.14; 95%CI= 1.10 to 1.17; p b .001). Again, the Haz-
ard Ratio decreased after adjusting for baseline levels of depressive and
anxiety symptoms but remained statistically signiﬁcant (HR = 1.07;
95%CI = 1.02 to 1.13; p b .01). The positive association between
somatisation and onset of depressive and/or anxiety disorders is also
shown in Fig. 1. The incidence of depressive and/or anxiety disorders
was higher in high somatisation groups.
Discussion
In this study, we prospectively investigated somatisation as a risk
factor for the onset of incident depressive or anxiety disorders as deter-
mined by a clinical interview.We found that somatisation increased the
risk of a subsequent incident depressive or anxiety disorder during four
years, over and above baseline depressive and anxious symptoms.
Methodological considerations
Since the NESDA cohort study includes detailed information on the
history, phenomenology and correlates of these disorders and multiple
assessments of depressive and anxiety disorders using clinical inter-
views, it offers a unique opportunity to prospectively investigate the re-
lationship between somatisation and the onset of depressive and
anxiety disorders. However, some methodological considerations
should bementioned. At baseline, we had information on only the pres-
ence and extent, but not on the history, duration and course of
Table 1
Baseline characteristics of study sample (n= 611).
Baseline characteristics All participants
n= 611
Depressive and/or anxiety
disorder during follow-up
n= 95
No depressive or anxiety
disorder during follow-up
n= 516
Age, M (SD)⁎ 41.0 (14.6) 36.5 (13.8) 41.8 (14.6)
Gender: female, n (%) 372 (61%) 65 (68%) 307 (60%)
Education level: years,M (SD) 12.9 (3.2) 12.7 (3.1) 13.0 (3.2)
Work status, n (%)⁎
Working 445 (73%) 58 (61%) 387 (75%)
Sickness beneﬁt/occupational disabled 25 (4%) 7 (7%) 18 (4%)
Not working 141 (23%) 30 (32%) 111 (22%)
Chronic condition: yes, n (%) 207 (34%) 26 (27%) 181 (35%)
Depressive symptoms: QIDS,M (SD)⁎ 3.42 (3.09) 6.16 (4.12) 2.91 (2.56)
Anxiety symptoms: BAI subjective scale,M (SD)⁎ 1.35 (1.97) 2.53 (2.50) 1.14 (1.76)
Somatisation: 4DSQ,M (SD)⁎ 5.04 (4.65) 8.66 (5.87) 4.37 (4.04)
⁎ Signiﬁcant difference (p b .05) between participants with and participants without incident depressive and/or anxiety disorder during 4-year follow-up.
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checked by a doctor to verify whether they could be explained by a so-
matic disorder. However, we adjusted for the presence of chronic so-
matic disorders that may explain symptoms in our analyses, and this
had no effect on the strength of the hazard ratios. Also, time to onset
of depressive and anxiety disorders was roughly determined. We re-
peated the analyses without including time to onset, but this did not
change our results. While there was, unavoidably, some attrition in
our study, analyses showed that differences between participants and
non-participants were small. Furthermore, inherent to the NESDA sam-
pling methods [17], our sample consisted of persons at high risk of de-
pressive and/or anxiety disorders as well as healthy controls. As a
result, this study reported higher incidence rates of depressive and anx-
iety disorders compared to the general population [24].
Our ﬁndings in context of the literature
Previous research has found a strong concurrent relationship be-
tween somatisation and depression [3,5,9]. Bekhuis et al. (2014) [5]
for example found that all types of depressive and anxiety disorders, ex-
cept for dysthymic disorder, were independently associated with all
clusters of concurrent somatic symptoms. Somatisation also has nega-
tive prognostic value as co-occurrence is predictive of a poorer treat-
ment response in depressed patients [11]. Several underlying
mechanisms have been proposed that may explain how these condi-
tions are related: 1) depression and anxiety may be a reaction to
somatisation, 2) somatisation may be part of, or a consequence of de-
pression and anxiety, and 3) that all of these conditions are just different
expressions and dimensions of a common underlying form of distress
[25]. From previous cross-sectional studies no conclusion can beTable 2
Hazard Ratios for incidence of depressive disorder, anxiety disorder, and depressive and/or anx
Depressive disorder HR
(95% CI)a
Somatisation
Crude association, per unit increase 1.13 (1.09 to 1.17)⁎
Somatisation
adjusted for age, gender, education, working status 1.14 (1.10 to 1.19)⁎
Somatisation
+chronic somatic disorder 1.15 (1.10 to 1.20)⁎
Somatisation
+depressive and/or anxiety symptoms 1.06 (1.01 to 1.12)⁎
HR = Hazard Ratio.
95% CI = 95% conﬁdence interval.
a During the 4-year follow-up, 95 participants became depressed and/or anxious: 71 partici
⁎ p b .05.drawn about these mechanisms. Findings pertaining to the ﬁrst propo-
sition,which can be considered to be the focus of the current study, have
thus far been mixed. A study in a community sample found that after
correction for depressive symptoms at baseline, somatisationmarginal-
ly predicted subsequent depressive symptoms at 5-year follow-up in
non-depressed women, but were not predictive in non-depressed
men [13]. A prospective community cohort study in the UK reported
that only a persistently high somatic symptom count was predictive of
poor self-reported mental health but a high somatic symptom count
at baselinewas not predictive [19]. Although each study has itsmethod-
ological limitations, an important restriction across the board is that, un-
like in our study, psychiatric history of depression or anxiety was either
not or not adequately taken into consideration. Thus, it was impossible
to discriminate between recurrence and incidence, but it can also con-
found the association between somatisation and subsequent depression
or anxiety as psychiatric history is an important predictor of these disor-
ders [20]. In our study, which was restricted to participants without a
lifetime history of a depressive or anxiety disorder, we found that
somatisation prospectively predicted these disorders above and beyond
baseline levels of depressive or anxiety symptoms, and, therefore, pro-
vided support for the ﬁrst mechanism mentioned above. Our results
may, however, also be explained by the thirdmechanism, which postu-
lates that depressive disorders, anxiety disorders and somatisation are
different expressions of a common underlying construct.
Somatisation and symptoms of depression and anxiety
Commonly used measures for depressive and anxiety symptoms
such as the IDS and BAI also assess somatic symptoms that accompany
or are part of depression and anxiety. To minimise difﬁculties iniety disorder at follow-up as predicted by baseline somatisation score (n= 611).
Anxiety disorder HR
(95% CI)a
Depressive and/or anxiety disorder HR
(95% CI)a
1.14 (1.09 to 1.18)⁎ 1.14 (1.10 to 1.17)⁎
1.17 (1.11 to 1.23)⁎ 1.15 (1.11 to 1.19)⁎
1.17 (1.11 to 1.23)⁎ 1.16 (1.11 to 1.20)⁎
1.13 (1.07 to 1.20)⁎ 1.07 (1.02 to 1.13)⁎
pants developed a depressive disorder and 48 participants developed an anxiety disorder.
Fig. 1. Incidence of depressive and/or anxiety disorders during 4-year follow-up (%), clas-
siﬁed according to somatisation score (n= 611).
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anxiety, we used the QIDS, which includes fewer items on somatic fea-
tures of depression and the subjective scale of the BAI which only focus-
es on subjective and cognitive aspects of anxiety. Furthermore, the
majority of somatisation measures currently available operationalise
somatisation as an increased somatic symptom count (e.g. PHQ-15,
SCL-90 somatisation subscale, 4DSQ somatisation subscale). Although
somatic symptom count is certainly a core feature of somatisation, it is
probably not very speciﬁc. Increased somatic symptom count as
measuredwith somatisation scalesmay, in this case, be found to predict
depression and anxiety, but questions remain. Is it actually the
‘somatisation’ (i.e. “the tendency to experience and communicate so-
matic stress and symptoms unaccounted for by pathological ﬁndings,
to attribute them to physical illness, and to seek medical help for
them” [1], p. 1359) that is predictive. To which condition can we attri-
bute the somatic symptoms? In line with DSM V [26,27], a step forward
may be to operationalise and develop more speciﬁc measures of
somatisation, which include cognitive criteria besides listing somatic
symptoms [28,29]. The concept and operationalisation of somatisation
aswell as its conceptual relationshipwith depressive and anxiety symp-
toms remain an important point of consideration and future study.Conclusions
High physical symptom levels (somatisation) predict incident de-
pressive and anxiety disorders during four years, over and above base-
line levels of depressive or anxiety symptoms, in a study sample
without a lifetime history of depressive and anxiety disorders.
Somatisation scores may, therefore, deserve extra clinical attention in
primary care. The 4DSQ offers such a symptom tool and is increasingly
used as such in countries around the world. Moreover, persons with
high somatisation scores represent a potential target group for preven-
tion of depressive and anxiety disorders as they have a higher risk of be-
coming depressed or anxious. In primary care, for instance, persons
with high somatisation scores could be monitored more closely in
shared care models with mental health nurses or start treatment, ac-
cording to recent primary care guidelines [30].Competing interests
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